Ohio Life Sciences

Q32025

Member Investor Portfolio Report

SPONSORED BY Precision Environments®

A letter from the president & CEO

Fellow Life Sciences Supporter,

It is my privilege to share the seventh edition of the Ohio Life Sciences Member Investor Portfolio Report—a reflection of the momentum, ingenuity, and investment shaping our state's growing life sciences economy. This quarter's edition highlights national shifts in innovation strategy, accelerating regulatory reform, and Ohio's continued rise as a destination for development, manufacturing, and talent.

Nationally, the FDA's new PreCheck pilot marks a major step toward faster, more predictable facility readiness, helping strengthen America's manufacturing base. Eli Lilly's TuneLab AI discovery platform launch and the industry's record licensing pace show how collaboration and data-driven science are redefining the frontier of drug development. Venture investment continues to favor fewer, larger, and more focused rounds, underscoring investor confidence in proven platforms and AI-enabled health technologies.

Here in Ohio, the momentum is unmistakable. Hikma Pharmaceuticals announced a $1B U.S. expansion, JobsOhio introduced new relocation incentives to attract STEM talent, and Ohio Life Sciences launched the Life Science Ready Community Designation Program to help cities and regions signal their readiness for life sciences growth. Together, these efforts show that Ohio is not only attracting world-class investment but also building the infrastructure and workforce to sustain it.

Across the Ohio Discovery Corridor, the alignment between research, manufacturing, and clinical excellence is creating one of the most integrated life science ecosystems in the country. Nearly 5,000 establishments and more than 63,000 jobs now span the full value chain from discovery to delivery—all within one state.

I invite you to explore this report and share it with your networks. It showcases the vision and collaboration that make Ohio a leader in life sciences today—and a model for how regions can grow together to shape the future of health innovation.

Eddie Pauline

PRESIDENT & CEO, OHIO LIFE SCIENCES

National Trends

The FDA's Regulatory Streamlining Program Pilot

The FDA's new PreCheck program, launched in September 2025, is a pilot initiative designed to streamline facility readiness and regulatory review for U.S. drug manufacturers. It allows companies—particularly generic-drug producers and CDMOs—to engage with the agency early during site design, construction, and qualification, enabling facilities to be "pre-checked" before a drug application is filed. This approach aims to decouple facility inspections from the product-review clock, reduce approval delays, and strengthen domestic manufacturing resilience.

Christopher Schilling, Chief Regulatory Officer at Forge Biologics, was one of 30 invited by the FDA to present at its public meetings; he described PreCheck as "a great opportunity," but emphasized the need for clearer FDA guidance on eligibility criteria, especially regarding contract manufacturers and facility expansions. Schilling also noted that separating facility readiness from application timelines could give companies more time to identify and correct compliance issues earlier in development.[1]

Manufacturing adeno-associated virus (AAV) in one of Forge Biologics' purpose-built cGMP suites.

Eli Lilly's New Drug Discovery Platform

Eli Lilly launched the Lilly TuneLab, an artificial intelligence and machine-learning (AI/ML) drug-discovery platform giving selected biotechnology companies access to models trained on Lilly's proprietary datasets, representing a research investment of over $1B. The dataset behind the platform covers drug disposition, safety, and preclinical data drawn from experiments with hundreds of thousands of unique molecules. Hosted by a third-party provider, the platform uses a federated-learning architecture to enable partners to run Lilly-trained models on their own data—and contribute model updates—without either side exposing raw proprietary data.

In a shift to a more collaborative early-stage biotech partner model, TuneLab plugs into Lilly's broader Catalyze360 ecosystem that can include venture funding via Lilly Ventures, lab or incubator space via Gateway Labs, and development expertise via ExploR&D. Initial participants include Insitro ($643M raised), Circle Pharma ($212M raised), Superluminal Medicines ($158M raised) and Firefly Bio ($94M raised).[2]

Life Science Workforce Insights

The Life Science Workforce Collaborative (LSWC) and TEConomy published their *2025 Life Sciences Workforce Trends Report*, collecting surveys of 500 companies, interviews with 200 industry executives, and an analysis of 2.9 million U.S. job postings from life sciences companies over the last four years.[3]

Life science industry employment has held steady above two million for five years, but in the last two years, industry job postings have declined. AI, machine learning, and industrial automation are likely culprits, creating both challenges and opportunities for companies and their employees.

The LSWC survey identified eight key use cases for AI/ML and 14 specialized skills that dominate job postings shown in Table 1 and Table 2.

TABLE 1

KEY AI/ML USE CASES, CITED BY INDUSTRY EXECUTIVES
Automation in Manufacturing and Operational Processes
Data Analytics and Decision Making
Drug Discovery and Development
Regulatory Compliance and Quality Control
Clinical Support
Customer Support
Supply Chain and Logistics Optimization
Recruitment and Talent Management

TABLE 2

SPECIALIZED SKILLS DOMINATING JOB POSTINGS
Python Programming
Data Sciences
Machine Learning
R Programming
Artificial Intelligence
Algorithms
SQL Programming
Data Visualization
PyTorch Machine Learning
Automation
TensorFlow
Scikit-Learn (Python)
Microsoft Azure
Tableau Business Intelligence

Investment Trends

Fewer Deals, Larger Bets

Overall, U.S. venture capital investments in Q3-25 showed a slight increase in dollars invested, but an 11% decline in deal count, continuing the trend of fewer deals with larger amounts, primarily for later-stage and AI-dominant companies. Venture dollars invested increased from $70.3B to $73.4B, while deal counts declined from 2,931 to 2,621.

In life sciences, venture investments and deal counts were both down from the prior quarter. Venture dollars invested into life science companies in Q3-25 were $7.4B, down 8% from $8.1B in Q2. Deal count also declined 17% from 446 deals in Q2 to 371 deals in Q3.[4]

Licensing Activities

Biopharma licensing deals totaled $181B in the first three quarters of 2025, on track to eclipse last year's total of $188.6B, with 8% of that value paid upfront, up from 6% in 2022. Biologics are leading the way in licensing, at $10B year-to-date, nearly double 2024's $5.4B. Medtech licensing deals are up, but the upfront portion declined to 4%, the smallest in nearly a decade.

Exits Are Accelerating

Q3's exit activity was the strongest since the pandemic, delivering $74.5B across 362 deals with seven unicorn IPOs completed. Medtech IPO activity is up with seven over $15M this year; however, biopharma activity remains quiet. Investors are cautiously optimistic about exit activity going forward, with anticipation of further interest rate cuts and an M&A friendly regulatory environment.[5]

$7.4B

INVESTED ACROSS 371 Q3 LIFE SCIENCE DEALS

$181B

BIOPHARMA LICENSING DEALS YTD

"Pitchbook | Venture Monitor" Pitchbook Data, Inc., 2025.



Clarametyx is rapidly advancing development of CMTX-101, a novel anti-biofilm antibody, with a favorable interim analysis on its Phase 2 study.

Ohio Trends

Hikma Commits to $1B U.S. Expansion

Hikma announced that it will invest $1B by 2030 to expand its U.S. operations to further develop, produce, and deliver a broad range of medicines for the U.S. healthcare system. A top three U.S. sterile injectable medicine supplier, Hikma boasts over 180 injectable products with an annual domestic production capacity of over 12 billion finished doses of essential medicines. Hikma announced its new expansion program—dubbed America Leans on Hikma: Quality Medicines Manufactured in the USA—at its state-of-the-art manufacturing and R&D facility in Columbus.[6]

JobsOhio's Relocation Program Offers Companies Up To $225,000

Life science companies in Ohio can access up to $225,000 per company through JobsOhio's relocation incentive program, which provides $15,000 for each qualifying new hire who moves to the state. This initiative strengthens Ohio's position as one of the most cost-effective and talent-ready locations for bioscience growth. With a deep university research base, affordable lab space, and a rapidly expanding biomanufacturing network, Ohio offers the funding, workforce, and infrastructure needed to recruit top talent and scale in the heart of the nation.[7]

Ohio's Biotech Network: An Integrated, Business-Friendly Ecosystem

Ohio is unique because life science innovations can advance from initial discovery through to patient delivery without leaving the state. With nearly 5,000 organizations and more than 63,000 professionals across the sector, Ohio now supports a fully integrated value chain—encompassing research, development, manufacturing, and distribution. This seamless setup reduces friction and helps biopharma companies accelerate the path from lab to market.

With no corporate income tax and a flat income tax rate of 2.75%, Ohio's policies and economic development programs have successfully attracted billions of new investments from industry leaders, including Amgen, Kimberly-Clark, Pharmavite, Intelliguard, and others.[8]

Most states have one to two major metropolitan areas where the majority of their life science ecosystem is clustered. Ohio has three metros with over two million people each: Cincinnati, Columbus, and Cleveland, also known as the Ohio Discovery Corridor. This powerful trio in one state includes leading hospitals, including Cleveland Clinic, University Hospitals of Cleveland, MetroHealth Medical Center, Nationwide Children's, Wexner Medical Center at The Ohio State University, Cincinnati Children's, and University of Cincinnati Medical Center

Life Science Ready Community Designation Program Launch

Ohio Life Sciences launched the Life Science Ready Community Designation Program in September to help cities, counties, and regions across Ohio demonstrate their readiness to attract and support life science companies. The program establishes criteria for municipalities to achieve, covering infrastructure, workforce, zoning, and access to innovation hubs.[9]

The newly released Life Sciences Industry Guide for Municipal Leaders provides local governments with a roadmap to prepare for biotech investment while giving companies and investors confidence that designated communities meet industry standards. Together, these tools strengthen Ohio's competitiveness by expanding the number of regions that are truly ready for life science growth.

Ohio's Class of 2025, Q3

$106M Raised

19 LIFE SCIENCE COMPANIES

Series A & Late Stage Companies

COMPANY	AMOUNT RAISED	DEAL TYPE	HQ LOCATION
Beam Benefits	$19,870,000	Series F+	Columbus
The Ridge Ohio	$18,000,000	Private Equity	Milford
Eikonoklastes Therapeutics	$13,560,000	Series B2	Cincinnati
Redi.Health	$6,000,000	Series B1	Columbus
Arrellio	$3,500,000	Series A	Columbus
Invirsa	$2,830,000	Series B1	Columbus
ReadySet Surgical	$2,300,000	Series A+	Cleveland
TOTAL	**$66,060,000**		

Early Stage Companies

COMPANY	AMOUNT RAISED	DEAL TYPE	HQ LOCATION
AndHealth	$15,000,000	Seed+ Round	Columbus
TandemStride	$5,500,000	Seed Round	Cleveland
JotPsych	$5,000,000	Seed Round	Cleveland
Tampa Lakeview Center	$4,260,000	Seed Round	Hilliard
ValCor Cath	$4,250,000	Seed Round	Ottawa Hills
Primum	$3,600,000	Seed Round	Columbus
MedaSync	$1,570,000	Seed+ Round	Cleveland
MDBee	$890,000	Seed Round	Toledo
smallTalk	$285,000	Pre-Seed	Chagrin Falls
EmpathEQ	UND	Accelerator/Incubator	Cincinnati
Kalix	UND	Pre-Seed	Centerville
Vampiro	UND	Seed Round	Columbus
TOTAL	**$40,355,000**		

Ohio Deal Dashboard, Q3



Deals by Funding Stage

- Late Stage
- Series A
- Early Stage

Early stage had the most deals with 13 followed by late stage with 4 and Series A with 2 deals.



Dollars by Funding Stage

- Late Stage
- Series A
- Early Stage

Early stage dollars led the pack with 55% of dollars raised, followed by late stage with 40% and Series A at just 5%.



Deals by Size

- $10M–99M
- $1M–9.9M
- $1k–999k
- Undisclosed

We had 4 deals over $10M this quarter with the largest group between $1–9.9M with 10 deals.



Dollars by Vertical

- Healthcare Services & Other
- Software & Solutions
- Therapeutics
- Devices & Diagnostics

Healthcare Services led with 54% of fundraising in Q3, followed by 27% for Software, 15% Therapeutics, and 4% Devices & Diagnostics.

OLS Funding Highlights, Q3

Neuros

$56M
SERIES E
July, 2025

$164M
FUNDING TO DATE
September, 2025

INVESTORS

IEQT · BF Belmont · Amzak Health · Aperture Venture Partners, LLC · CUP Osage University Partners · Sectoral Asset Management · USVP U.S. Venture Partners

Neuros Medical is the maker of the Altius® Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain.

beam

$19.8M
SERIES F
August, 2025

$303M
FUNDING TO DATE
September, 2025

PRIOR INVESTORS

Trinity Capital · Mercato · Chestnut Street Ventures · Kleiner Perkins · Nationwide · DRIVE

Beam Benefits provides simpler, smarter employee benefits, including dental, vision, life, disability, and supplemental health.

andhealth

$15M
EARLY STAGE
August, 2025

$72M
FUNDING TO DATE
September, 2025

PRIOR INVESTORS

Francisco Partners · Twofold · Health 2047 Capital Partners · Kirkland & Ellis

Andhealth is a chronic disease clinic helping people reclaim their lives from migraines.

eikonoklastes™ THERAPEUTICS

$13.5M
SERIES B2
August, 2025

$25M
FUNDING TO DATE
September, 2025

PRIOR INVESTORS

JobsOhio · cincytech · rev1 ventures

Eikonoklastes Therapeutics is an early-stage biopharmaceutical company focused on rapidly advancing innovative medicines for numerous areas of significant unmet clinical need, starting with neurodegenerative diseases.

TANDEMSTRIDE
Moving forward, together

$5.5M
SEED FINANCING
September, 2025

$5.5M
FUNDING TO DATE
September, 2025

INVESTORS

tmv. · University Hospitals Ventures · M25 · FLARE CAPITAL PARTNERS · lightbank · JumpStart Ventures · NORTH COAST VENTURES

TandemStride is building a resilient survivor community by connecting individuals with shared, lived experiences in trauma to improve outcomes and quality of life for survivors.

JotPsych

$5M
SEED FINANCING
July, 2025

$5.31M
FUNDING TO DATE
September, 2025

INVESTORS

Base10

JotPsych is the premier AI-scribe for behavioral health, saving clinicians 90% of their documentation time. JotPsych has scribed for over one million patient encounters across the U.S., Canada, Australia, and New Zealand.

ValCor

$4.25M
SEED FINANCING
August, 2025

$4.25M
FUNDING TO DATE
September, 2025

INVESTORS

University Hospitals Ventures

ValCor Cath offers a two-in-one guided catheter for cardiac surgical procedures, enabling patients to get treatment for their heart conditions.

ReadySet
Operate in Harmony

$2.3M
SERIES B+
July, 2025

$15.4M
FUNDING TO DATE
September, 2025

INVESTORS

Riverside

ReadySet Surgical is a surgical inventory management platform designed to enhance transparency within the vendor-managed supply chain.

medasync

$1.57M
SEED FINANCING
August, 2025

$3.64M
FUNDING TO DATE
September, 2025

INVESTORS

OMEGA Healthcare Investors, Inc.

Medasync develops reimbursement software designed to automate and streamline the operations of skilled nursing operators.

invirsa

$2.83M
SERIES B+
August, 2025

$14.3M
FUNDING TO DATE
September, 2025

PRIOR INVESTORS

JobsOhio
JumpStart Ventures
Ohio Innovation Fund
cincytech
rev1 ventures

Invirsa is developing a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.

PRiMUM

$3.6M
SEED FINANCING
September, 2025

$11.1M
FUNDING TO DATE
September, 2025

INVESTORS

FCA Venture Partners
North Coast Ventures

Primum is a digital platform remotely connecting physicians to allow for more localized, confident patient care.

OLS Company Highlights

Neuros Medical Reports First Commercial Patient Implant and $56M Series D Financing

Neuros Medical announced that the first commercial patient in the U.S. successfully received an FDA-approved Altius implant at Baylor Scott & White Heart and Vascular Hospital in Dallas; the company also completed its Series D financing, bringing another $56M of capital to fuel its growth.

“The first commercial implantation of the Altius System represents a significant advancement in the treatment of a large unmet medical need in chronic post-amputation pain and a critical step forward for expanding new indications for neuromodulation therapies,” said David Veino, president and CEO of Neuros Medical. “We are proud to offer new hope to patients who have limited options for durable pain relief.”

Neuros successfully closed its oversubscribed Series D financing of $56M in July, led by EQT Life Sciences, with participation from existing investors including US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, Aperture Venture Partners, and several long-standing and committed investors.

Although Neuros is headquartered in Aliso Viejo, California, the company has deep Ohio roots. Cleveland’s Jon Snyder co-founded the company in 2008 based on nerve-block technology from Case Western Reserve University, raised $40M in venture capital and strategic partner investment, completed two clinical studies, and developed the go-to-market product over a 10-year period. Neuros is an excellent example of successful technology commercialization from universities in the Midwest through the clinical trial process and into patients.

DASI Simulations Signs Cleveland Clinic and Medtronic Strategic Development Deals

DASI Simulations announced an agreement with Cleveland Clinic to utilize DASI’s PrecisionTAVI™ technology to support planning and treatment for current TAVR patients and to co-develop the next generation of AI predictive modeling solutions for the treatment of structural heart diseases. The goal is to create the world’s first AI-powered “co-pilot” system for catheterization labs.

DASI Simulations also announced a strategic partnership with Medtronic to enhance access to DASI’s PrecisionTAVI™ technology, optimizing outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) in the United States.

“Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide,” said Teri Sirset, MS, founder, president, and chief executive officer of DASI Simulations. “Together, we’re demonstrating how predictive modeling can drive operational efficiency, support clinical decision-making, and elevate the standard of care.”

Enable Injections Announces enFuse System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK

Enable Injections announced that their enFuse on-body injector system received regulatory approval in Brazil and MRHA Medical Device Registration in the UK.

The approval in Brazil marks a milestone in Enable’s partnership with Sobi—announced in September 2024—with plans to develop and distribute the enFuse system for the administration of Empaveli®/Aspaveli® in Sobi territories.

The enFuse on-body injector features hands-free, hidden needle drug delivery through a simple injection under the skin instead of time-consuming and resource-intensive intravenous insertion. The enFuse system is designed to enhance the patient treatment experience by streamlining and improving at-home self-administration or in-clinic subcutaneous delivery of large volumes of pharmaceutical and biologic therapeutics.

Clarametyx Biosciences' Favorable Clinical Trial Update

Clarametyx Biosciences reported a favorable interim analysis from its randomized, double-blind Phase 1b/2a clinical trial of CMTX-101, a first-in-class immune-enabling antibody designed to disrupt bacterial biofilms and enhance antibiotic efficacy in cystic fibrosis (CF)-associated pulmonary infections. The independent data monitoring committee recommended continuation of the study, which has now been approved for expansion to additional sites and participants. CMTX-101 has received FDA Fast Track and Qualified Infectious Disease Product (QIDP) designations, with full data expected in early 2026.

Forge Biologics Invited to D.C. for Input on the FDA's New PreCheck Program

Forge Biologics was one of just 30 manufacturing companies invited to present during the FDA's public meeting on Onshoring Manufacturing of Drugs and Biological Products, focused on the newly proposed PreCheck program. The purpose of the session was to gather industry feedback on how FDA PreCheck can best accelerate the establishment, readiness, and oversight of pharmaceutical manufacturing facilities to promote manufacturing in the U.S.

Forge's Chief Regulatory Officer, Christopher Shilling, traveled to Washington, D.C. to represent the gene therapy manufacturing community as part of the discussion that spanned generics, small molecules, biologics, and gene therapy, underscoring Forge's role as a leading U.S.-based CDMO shaping the regulatory dialogue for the life science industry.

Haima Therapeutics Receives $4M of DARPA SBIR Contracts

Haima Therapeutics, a preclinical-stage biopharma company developing platelet-inspired therapeutics for trauma and surgical bleeding, announced the award of two Small Business Innovation Research (SBIR) contracts from the Defense Advanced Research Projects Agency (DARPA), totaling $4M. Each $2M award will accelerate the development of SynthoPlate, Haima's fully synthetic, platelet-mimetic hemostatic drug, through critical preclinical and manufacturing milestones enabling an IND submission.

These awards build directly on Haima's successful contributions to DARPA's Fieldable Solutions for Hemorrhage with Advanced Resuscitation Products (FSHARP) program, which is advancing a whole blood surrogate containing SynthoPlate, an oxygen carrier, and dried plasma. This new funding enables Haima to conduct IND-enabling preclinical safety studies, scale manufacturing, and prepare for first-in-human clinical evaluation of SynthoPlate as a battlefield and civilian trauma solution.

Neucore Bio Receives Two Phase 1 STTR Grants From NIH and NSF

NATIONAL INSTITUTES OF HEALTH (NIH) PHASE 1 STTR GRANT

Neucore Bio received a $350,000 STTR Phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH). This will support research on Neucore's targeted exosome platform to deliver an RNA-based therapy to treat Charcot-Marie-Tooth Disease Type 1a (CMT1A).

NATIONAL SCIENCE FOUNDATION (NSF) PHASE 1 STTR GRANT

Neucore Bio also received a $304,000 STTR Phase 1 grant from the National Science Foundation for Research on the scalability of exosome-based therapeutics for genetic disease.

“Our goal with this project is to reduce the manufacturing complexity and cost of eEV-based therapeutics, which presents a barrier to accessible, scalable treatments that could offer significant benefit for people affected by a wide range of genetic diseases,” said Kenneth Morand, Ph.D., Co-founder and Chief Executive Officer, Neucore Bio.

Nexture Bio Launches Two New Tissue Engineering Products and a New Product Line

Nexture Bio expanded its commercial portfolio with the launch of two new tissue engineering products: the Porous Sponge Scaffold and the Pea Protein Microcarrier. Both are now available through the company’s e-commerce platform. To better serve key industries, Nexture also introduced a new applications section on its website, with dedicated pages for cellular agriculture, tissue engineering, and cell therapy.

Nexture also launched a new product line: electrospun bioactive-loaded strips for the delivery of supplements, vitamins, and drugs through buccal mucosa tissue. Although similar technologies exist on the market, applications have been limited to controlled drug delivery, as the strips are typically made of synthetic polymers. Nexture’s product is a dissolvable, edible strip that provides a novel bioavailability improvement.

DNA Nanobots, Inc., Most Innovative Product Development Company, Receives SBIR Grant

Columbus Business First selected DNA Nanobots as one of the Most Innovative Product Development Companies as part of its Innovators in Healthcare and Life Sciences awards.

The company also announced that it has received a Phase I SBIR Grant from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) to support development of the company’s proprietary non-viral gene therapy platform.

In 2025, the company also initiated preclinical testing of its lead candidate for muscular dystrophy, completed scale-up of its scaffold production pipeline, and built a team with deep expertise in synthetic biology, gene therapy, and nanofabrication.

TechStars Graduate smallTalk Completes an Oversubscribed Seed Round

smallTalk is dedicated to supporting the healthy development of premature and medically fragile infants through the power of voice. Their innovative products are designed specifically for the Neonatal Intensive Care Unit (NICU), where early sensory experiences—especially those involving the voice—play a crucial role in brain development, emotional bonding, and long-term outcomes.

smallTalk announced the close of its oversubscribed Seed Round of $285,000. Investors include Nationwide Children’s Hospital, Ohio State Early Investor Network, Athens Ohio Investment Alliance, EC Angels, individual angels, and company management. smallTalk is a graduate of TechStars Columbus, powered by The Ohio State University.

1 Fraiser Kansteiner, FDA launches generics pilot program, advances facility PreCheck proposal in bid to incentivize US drug manufacturing, Fierce Pharma, October 2025.

2 Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment, Lilly, September 2025.

3 *2025 Life Sciences Workforce Trends,* Life Sciences Workforce Collaborative and TEConomy Partners, LLC, 2025.

4 *Q3 2025 PitchBook–NVCA Venture Monitor,* PitchBook, October 2025.

5 *Q3 2025 Biopharma Licensing and Venture Report,* JP Morgan, October 2025.

6 Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines, Hikma, June 2025.

7 Ohio Life Sciences Companies: Access Incentive Dollars Now, Ohio Life Sciences, August 2025.

8 Ohio's Biotech Network: Accelerating Drug Development with an End-to-End Ecosystem, Ohio Life Sciences, September 2025.

9 Ohio Life Sciences Association Launches Life Science Ready Community Designation Program and Industry Guide, Ohio Life Sciences, September 2025.

EDITOR

SmartMoneyVentures, LLC

DESIGN

SPOKE.

Information in this report was compiled primarily from publicly available information, reports, press releases and/or company representatives.

Please email any additions or corrections to data@SmartMoneyVentures.com.

The mission of Ohio Life Sciences is to align the life sciences ecosystem in the State of Ohio, building collaborative partnerships and advocating for policies and funding that will help to accelerate life science priorities and drive sustainable economic growth.

OHIOLIFESCIENCES.ORG

OHIO LIFE SCIENCES

614.675.3686